GAB2在卵巢癌组织中的表达及其与预后的相关性

doi:10.11904/j.issn.1002-3070.2022.02.009

摘要/Abstract

摘要： 目的评估卵巢癌组织中Grb相关结合蛋白2(Grb-associated binding protein 2,GAB2)的表达及其与预后的关系。方法收集南通大学附属肿瘤医院2013年1月—2016年1月手术切除的119例卵巢癌组织及癌旁组织,利用免疫组织化学染色法检测组织中GAB2的表达情况,并分析其表达量与临床特征和总生存期(Overall survival,OS)的关系。利用Cox比例风险模型分析影响卵巢癌患者OS的危险因素。构建基于Cox比例风险模型的Nomogram预后模型预测卵巢癌患者3年和5年生存率。结果与癌旁组织相比,GAB2在癌组织中表达增加(P＜0.001)。我们还发现GAB2表达量与FIGO分期(P=0.004)、初诊时CA125水平(P=0.005)和铂耐药性复发(P＜0.001)有关。Kaplan-Meier生存曲线表明GAB2的高表达与患者OS的下降有关(P＜0.001)。单因素分析结果显示,GAB2表达量、FIGO分期、初诊时CA125水平和铂耐药性复发与卵巢癌患者OS相关(P＜0.05)。多因素分析显示,GAB2表达水平是影响卵巢癌患者OS的独立因素。Nomogram预后模型对卵巢癌患者3年和5年生存率的预测能力较好(C指数为0.801)。结论 GAB2的表达水平能预测卵巢癌患者的预后,有望成为卵巢癌治疗的潜在靶点。

关键词: 卵巢癌, Grb相关结合蛋白2, 预后

Abstract: Objective The aim of this study was to evaluate the expression of Grb-associated binding protein 2(GAB2)in patients with ovarian cancer and its relationship with prognosis.Methods A total of 119 ovarian cancer tissues and adjacent tissues were collected from The Affiliated Tumor Hospital of Nantong University from January 2013 to January 2016.The expression of GAB2 in the tissues was detected by immunohistochemical staining,and its correlation with clinical characteristics was analyzed.The relationship between GAB2 expression and survival was analyzed by Kaplan-Meier survival curve.Cox proportional hazard regression model was used to analyze the risk factors affecting the prognosis of ovarian cancer patients.Finally,a Nomogram prognosis model was constructed to predict 3-year and 5-year survival rates of ovarian cancer patients based on Cox proportional hazard regression model.Results Compared with adjacent tissue,the expression of GAB2 was increased in tumor tissues(P＜0.001).In addition,the level of GAB2 was significantly correlated with FIGO stage(P=0.004),the level of CA125 at initial diagnosis(P=0.005),and platinum-resistant recurrence(P＜0.001).Kaplan-Meier curves showed that the high expression of GAB2 was associated with the decrease of OS(P＜0.001).Univariate analysis showed that the level of GAB2,FIGO stage,CA125 level at initial diagnosis and platinum-resistant recurrence were associated with OS in ovarian cancer patients(P＜0.05).Multivariate analysis showed that GAB2 expression was an independent factor affecting the prognosis of ovarian cancer patients.The Nomogram prognostic model had good predictive power for 3-year and 5-year survival in ovarian cancer patients,with a C-index of 0.801.Conclusion The expression of GAB2 can predict the prognosis of ovarian cancer patients,and is expected to be a potential target for ovarian cancer treatment

Key words: Ovarian cancer, Grb-associated binding protein 2, Prognosis

中图分类号:

R711.75

尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.

YIN Yi, OU Chaoyang, HE Aiqin. Expression of GAB2 in ovarian cancer and its correlation with prognosis[J]. Journal of Practical Oncology, 2022, 36(2): 150-155.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.02.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I2/150

参考文献

1 Momenimovahed Z,Tiznobaik A,Taheri S,et al.Ovarian cancer in the world:epidemiology and risk factors[J].Int J Womens Health,2019,11(1):287-299.
2 Torre LA,Trabert B,DeSantis CE,et al.Ovarian cancer statistics,2018[J].CA Cancer J Clin,2018,68(4):284-296.
3 Fitzmaurice C,Dicker D.The global burden of cancer 2013:global burden of disease cancer collaboration[J].JAMA Oncol,2015,1(4):505-527.
4 Narod S.Can advanced-stage ovarian cancer be cured?[J].Nat Rev Clin Oncol,2016,13(4):255-261.
5 孙帅.吉西他滨联合顺铂治疗晚期复发性卵巢癌 18 例疗效观察[J].肿瘤学杂志,2018,24(9):896-899.
6 Zhang W,Samelson LE.The role of membrane-associated adaptors in T cell receptor signalling[J].Semin Immunol,2000,12(1):35-41.
7 Gu H,Neel BG.The“Gab”in signal transduction[J].Trends Cell Biol,2003,13(3):122-130.
8 Brummer T,Schramek D,Hayes VM,et al.Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the GAB2 docking protein[J].J Biol Chem,2006,281(1):626-637.
9 Huang E,Cheng SH,Dressman H,et al.Gene expression predictors of breast cancer outcomes[J].Lancet,2003,361(9369):1590-1596.
10 Herrera Abreu MT,Hughes WE,Mele K,et al.GAB2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation[J].Mol Biol Cell,2011,22(1):105-116.
11 Dunn GP,Cheung HW,Agarwalla PK,et al.In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene[J].Proc Natl Acad Sci U S A,2014,111(3):1102-1107.
12 Liu X,Wu A,Wang X,et al.Identification of metabolism-associated molecular subtype in ovarian cancer[J].J Cell Mol Med,2021,25(20):9617-9626.
13 李委佳,贾朝阳,冯书君,等.NDRG4通过Wnt/β-catenin信号转导通路抑制卵巢癌细胞的迁移和侵袭能力[J].实用肿瘤杂志,2019,34(6):497-502.
14 Yamada K,Nishida K,Hibi M,et al.Comparative FISH mapping of GAB1 and GAB2 genes in human,mouse and rat[J].Cytogenet Cell Genet,2001,94(1/2):39-42.
15 Sun B,Jensen NR,Chung D,et al.Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer[J].Am J Cancer Res,2019,9(1):145-159.
16 Bunda S,Burrell K,Heir P,et al.Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis[J].Nat Commun,2015,6(1):8859.
17 Zhang X,Dong Z,Zhang C,et al.Critical role for GAB2 in neuroblastoma pathogenesis through the promotion of SHP2/MYCN cooperation[J].Cell Rep,2017,18(12):2932-2942.
18 Cheng Z,Sun W,Ni X,et al.GAB2 inhibits chondrocyte apoptosis through PI3K-AKT signaling in osteoarthritis[J].Int J Clin Exp Pathol,2020,13(3):616-623.
19 Tian J,Zhang H,Mu L,et al.The miR-218/GAB2 axis regulates proliferation,invasion and EMT via the PI3K/AKT/GSK-3β pathway in prostate cancer[J].Exp Cell Res,2020,394(1):112128.
20 Ding C,Luo J,Fan X,et al.Elevated GAB2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels[J].J Exp Clin Cancer Res,2017,36(1):56.
21 Duckworth C,Zhang L,Carroll SL,et al.Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression[J].Oncogene,2016,35(31):4036-4047.
22 Berkel C,Cacan E.GAB2 and GAB3 are expressed in a tumor stage-,grade-and histotype-dependent manner and are associated with shorter progression-free survival in ovarian cancer[J].J Cell Commun Signal,2021,15(1):57-70.

[1]	王洪英, 李岩, 韩鑫浩, 魏孝礼, 贾慧珣, 袁文娟, 张秋菊. 基于免疫相关lncRNAs的胃癌早期诊断和预后风险模型的构建和验证[J]. 实用肿瘤学杂志, 2022, 36(2): 119-126.
[2]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[3]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[4]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[5]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[6]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.
[7]	陈奕心, 孙轶华, 程洋洋, 何凯桐, 郭婷. 术前炎症相关指标与可切除胃癌患者预后的相关性[J]. 实用肿瘤学杂志, 2021, 35(6): 517-522.
[8]	卢俊蓉, 王惠文, 何东风. SALL4高表达在食管鳞癌临床病理及预后判定中的意义[J]. 实用肿瘤学杂志, 2021, 35(5): 420-425.
[9]	余幼林, 余军林, 胡超华, 沈雄山, 李卫民, 卢婷, 杨峰, 杨青青, 刘程浩. 基于生物信息学方法分析LAYN在甲状腺癌中临床预后价值及对免疫细胞浸润的影响[J]. 实用肿瘤学杂志, 2021, 35(4): 357-364.
[10]	刘文, 乔文波. 程序性死亡蛋白1及其配体在结直肠癌中的临床研究现状[J]. 实用肿瘤学杂志, 2021, 35(4): 370-375.
[11]	董晓平, 张雪, 郭冬利, 贺宇彤. 肺鳞状细胞癌预后相关影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(4): 380-385.
[12]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[13]	秘嘉庆, 秦倩, 马惠涵, 马梅杰, 冯勤梅. TTK在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 188-192.
[14]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[15]	张文文,姜亮亮(综述),王晶(审校). CAR-T疗法在卵巢癌中的应用前景[J]. 实用肿瘤学杂志, 2021, 35(1): 59-63.